The file's text, extracted by GovTribe without its formatting.
BPA
| UF BPA NDC Price List for the May 2026 DoW P&T Meeting | | | |
| DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | Quotes due: | April 27, 2026 |
| Formulary Notes | | | |
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. | | | |
Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent(s) before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service. The P&T Committee may consider approving specialist(s) bypass and/or an automated drug look-back (up to 720 days) for the step-preferred (before-step) agent.
Biosimilar Step Therapy Addendum: No grandfathering may apply. Biosimilars are therapeutically equivalent to the reference product.
| • | For drugs in this subclass, the P&T Committee will maintain the TIBS class step preference (i.e., adalimumab) for the indications which it has FDA’s approval. |
| • | Agents with RFQ not submitted or selected may be designated non-step preferred (after-step). |
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #2 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #3 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #5 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #9 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
| | Blanket Purchase Agreement Appendix – Newly Approved Drug | | | | | | |
| #10 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Price per NDC | Package Size | Price per Unit |
| | One or more agents UF and after step | | | | | | |
| | Scenario 1 | 253TB16G1UFAS1M | Uniform Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | 253TB16G1NFAS1M | Non-Formulary | | | | |
| After-Step Therapy | 1 or more | | | NO QUOTE | | | | |
| | | | | | If cell highlights red, please confirm intent not to submit a quote | | |
ADP (non-FAMP Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | | | |
| DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | Quotes due: | April 27, 2026 |
| Formulary Notes | | | |
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. | | | |
Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent(s) before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service. The P&T Committee may consider approving specialist(s) bypass and/or an automated drug look-back (up to 720 days) for the step-preferred (before-step) agent.
Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process requires new and current patients to complete an adequate trial of the step-preferred (before-step) biosimilar(s) before a non-step-preferred (after-step) biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.
| • | The P&T Committee will maintain the TIBS class step preference (i.e., adalimumab) for the indications which it has FDA’s approval. |
| • | Agents with RFQ not submitted or selected may be designated non-step preferred (after-step). |
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
| | Additional Discount Program Appendix – Newly Approved Drug | | | | | | | | |
| #5 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
| | Additional Discount Program Appendix – Newly Approved Drug | | | | | | | | |
| #10 | DoW Uniform Formulary Class: | | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | | April 27, 2026 |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND | |
| | Formulary Scenarios | Condition Set # | Formulary Category Description | One of (x) Number of Brand Agents | Non-FAMP Price of Drug Per FCP Package** | Additional Offered Refund Per FCP Package** | Current Annual Federal Ceiling Price Per FCP Package** | Standard Refund Per FCP | Total Calculated Retail Refund Per FCP Package* |
| | One or more agents T2 and after step | | | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | | | |
| After-StepTherapy | 1 or more | | | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | | | |
| After-Step Therapy | 1 or more | | | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | | | |
ADP (WAC Discount)
| UF ADP Appendix for the May 2026 DoW P&T Meeting | | | |
| DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | P&T Committee Meeting: | May 6-7, 2026 |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | Quotes due: | April 27, 2026 |
| Formulary Notes | | | |
| Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program. | | | |
Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent(s) before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service. The P&T Committee may consider approving specialist(s) bypass and/or an automated drug look-back (up to 720 days) for the step-preferred (before-step) agent.
Biosimilar Step Therapy Addendum: Since biosimilars are equivalent to the reference product, no grandfathering will apply. No Grandfathering: a prior authorization process requires new and current patients to complete an adequate trial of the step-preferred (before-step) biosimilar(s) before a non-step-preferred (after-step) biosimilar is provided to the patient at any MTF, Retail, or Mail point of service.
| • | The P&T Committee will maintain the TIBS class step preference (i.e., adalimumab) for the indications which it has FDA’s approval. |
| • | Agents with RFQ not submitted or selected may be designated non-step preferred (after-step). |
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | TARGETED IMMUNOMODULATORY BIOLOGICS | | P&T Committee Meeting: | May 6-7, 2026 | |
| DoW Uniform Formulary Subclass: | INTERLEUKIN 1 (IL-1), INTERLEUKIN 6 (IL-6), AND CYTOTOXIC T-LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4) | | Quotes due: | April 27, 2026 | |
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
| | Formulary Scenarios | Condition Set # | Formulary Category | One of (x) Number of Brand Agents | WAC Price of Drug | WAC Discount* | Total Calculated Retail Refund per Package |
| | One or more agents T2 and after step | | | | | | |
| | Scenario 1 | 253TB16G1T2AS1M | Tier 2 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | 253TB16G1T3AS1M | Tier 3 | | | | |
| After-Step Therapy | 1 or more | | | | | | | |
| | | | | | | If cell highlights red, please confirm intent not to submit a quote | |
Defense Health Agency